| Prev Close | 3.21 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 1.69 / 5.10 |
| Avg Volume | 72.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 7.05M |
| Market Cap | 23.05M |
| EPS | -2.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Opexa Therapeutics Announces Supportive Preclinical Study Results For Its Neuromyelitis Optica (NMO) Program
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized otherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced results of...
Opexa Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported...
Opexa Therapeutics Announces News Release Schedule For Third Quarter 2015 Financial Results
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will...
Opexa Therapeutics To Host Analyst And Investor Event On November 10 In New York
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that...
Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it...
Opexa Therapeutics To Present At BIO Investor Forum
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that...
Opexa Announces Granting Of New T-cell Patents Covering Tcelna®; Patent Estate Increases To 160 Issued Patents
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced the...
5 Stocks Under $10 Set to Soar
These under-$10 stocks are poisted to trade higher from current levels.
Opexa Announces Reverse Stock Split
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that...
Opexa Secures Private Funding For Its NMO Orphan Development Program, Including Planned Phase I/II Clinical Study
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that...
Opexa Therapeutics To Present At September Conferences
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that...
Opexa Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported...
Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss Second Quarter 2015 Financial Results
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will...
Opexa Therapeutics CEO To Present At BIO 2015 International Convention
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K.
Opexa Hires Experienced Pharmaceutical Executive As Vice President Of Business Development
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), is pleased to announce...
Trade-Ideas: Opexa Therapeutics (OPXA) Is Today's Weak On High Relative Volume Stock
Trade-Ideas LLC identified Opexa Therapeutics (OPXA) as a weak on high relative volume candidate
Today's Weak On High Volume Stock: Opexa Therapeutics (OPXA)
Trade-Ideas LLC identified Opexa Therapeutics (OPXA) as a weak on high relative volume candidate
Opexa Therapeutics To Present At The 2015 Marcum Microcap Conference
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K.
Opexa Therapeutics CEO Invited To Participate In Multiple May Conferences
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K.
Opexa Therapeutics Reports First Quarter 2015 Financial Results And Provides Corporate Update
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial results for the three...
Opexa Therapeutics Announces News Release And Conference Call Schedule To Discuss First Quarter 2015 Financial Results
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will...
Opexa Therapeutics Invited To Present Biomarker Data From NMO Patients At The American Academy Of Neurology (AAN) 2015 Annual Meeting
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has been invited...
Opexa Therapeutics, Inc. Announces Completion Of Rights Offering
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has completed...
Opexa Therapeutics Reminds Shareholders That Rights Offering Expires On April 8, 2015 At 5:00 PM ET
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), provides a reminder to shareholders that...
Opexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date And Time Is Tuesday, March 10, 2015 At 4:00 PM ET
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), provides shareholders a reminder of its...
Opexa Amends Agreement With Merck Serono And Receives Additional $3 Million Payment To Support Ongoing Development Of Tcelna® For Multiple Sclerosis
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has amended its...
Opexa Therapeutics, Inc. Announces Record Date And Subscription Price For Rights Offering
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has set 5:00 p.
Opexa Therapeutics Reports Year End 2014 Financial Results And Provides Corporate Update
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial results for the year...
